Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Diazoxide × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Gastrointestinal 1 Endocrine 1

Conditions

Hypoglycemia 1 Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

telotristat ethyl 3 lutetium Lu 177 dotatate 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 veliparib 1 pasireotide 1 gallium Ga 68 dotatate 1 Tretinoin 1 Temozolomide 1 Isotretinoin 1 Introns 1 Everolimus 1 Diazoxide 1 Capecitabine 1 3-Iodobenzylguanidine 1 177Lu-octreotate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡